Boston Scientific lowers FY2026 adjusted EPS and sales guidance

Boston Scientific lowered its FY2026 adjusted EPS guidance from $3.28-$3.32 to $3.16-$3.18, versus the $3.23 estimate, and cut FY2026 sales guidance from $21.178B-$21.379B to $20.927B, versus the $21.143B estimate.

Detected & updated continuously · Source: Nebula